Daily Stock Analysis, ACER, Opexa Therapeutics Inc, priceseries

Opexa Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
1.70
Close
1.53
High
1.77
Low
1.50
Previous Close
1.72
Daily Price Gain
-0.19
YTD High
7.25
YTD High Date
Feb 20, 2020
YTD Low
1.08
YTD Low Date
Mar 23, 2020
YTD Price Change
-2.26
YTD Gain
-59.63%
52 Week High
28.25
52 Week High Date
Apr 11, 2019
52 Week Low
1.08
52 Week Low Date
Mar 23, 2020
52 Week Price Change
-22.56
52 Week Gain
-93.65%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Aug 3. 2018
21.10
Aug 16. 2018
26.27
9 Trading Days
24.52%
Link
LONG
Aug 17. 2018
28.94
Sep 6. 2018
31.32
13 Trading Days
8.24%
Link
LONG
Dec 31. 2018
20.12
Jan 24. 2019
24.12
16 Trading Days
19.89%
Link
LONG
Sep 4. 2019
2.60
Sep 24. 2019
3.34
14 Trading Days
28.63%
Link
LONG
Jan 9. 2020
3.86
Jan 24. 2020
4.28
10 Trading Days
10.80%
Link
LONG
Feb 6. 2020
4.51
Feb 24. 2020
4.76
11 Trading Days
5.45%
Link
LONG
Mar 25. 2020
1.97
Mar 27. 2020
2.10
2 Trading Days
6.85%
Link
Company Information
Stock Symbol
ACER
Exchange
NasdaqCM
Company URL
http://www.opexatherapeutics.com
Company Phone
(281) 272-9331
CEO
Neil K. Warma
Headquarters
Texas
Business Address
2635 TECHNOLOGY FOREST BLVD., THE WOODLANDS, TX 77381
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001069308
About

Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX.

Description

Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized immunotherapy to treat multiple sclerosis (MS) and other autoimmune diseases based on its proprietary T-cell technology. The company's lead product candidate is Tcelna, a novel T-cell immunotherapy, which is in Phase IIb clinical development for the treatment of patients with secondary progressive MS. It is also developing OPX-212 as an autologous T-cell immunotherapy that is in preclinical development to treat neuromyelitis optica. The company was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in June 2006. Opexa Therapeutics, Inc. was founded in 2003 and is based in The Woodlands, Texas.